Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany

Albrecht Stenzinger, Anders Edsjö, Carolin Ploeger, Mikaela Friedman, Stefan Fröhling, Valtteri Wirta, Thomas Seufferlein, Johan Botling, Justus Duyster, Michael Akhras, Robert Thimme, Thoas Fioretos, Michael Bitzer, Lucia Cavelier, Peter Schirmacher, Nisar Malek, Richard Rosenquist, Anna Lindstrand, Anna Wedell, David GisselssonErik Melén, Gisela Helenius, Hans Ehrencrona, Lars Engstrand, Lars Palmqvist, Lars Åke Levin, Lovisa Lovmar, Maréne Landström, Martin Hallbeck, Mia Wadelius, Per Sikora, Ambros J. Beer, Anna L. Illert, Jan Budczies, Konstantin Nikolaou, Oliver Kohlbacher, Peter Horak, Peter Kuhn, Christopher Schroeder, Melanie Boerries, Silke Lassmann, Verena I. Gaidzik

Publikation: Beitrag in FachzeitschriftÜbersichtsartikelBegutachtung

21 Zitate (Scopus)

Abstract

Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.

OriginalspracheEnglisch
Seiten (von - bis)242-254
Seitenumfang13
FachzeitschriftSeminars in Cancer Biology
Jahrgang84
DOIs
PublikationsstatusVeröffentlicht - Sept. 2022

Fingerprint

Untersuchen Sie die Forschungsthemen von „Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren